In this article, we will discuss Durvalumab (Clinical Studies-9). So, let’s get started.
The major efficacy outcome measures were progression-free survival (PFS) as assessed by a BICR v1.1, and overall survival (OS). Additional efficacy outcome measures included ORR and DoR assessed by BICR.